ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin
| Autor: | Larry Baum, Edmund K. Li, Lai-Shan Tam, Tanya T W Chu, Emily Poon, Miao Hu, Gary T.C. Ko, Brian Tomlinson, Sandra S.H. Lui, Vivian W Y Lee |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Abcg2 Hypercholesterolemia Low density lipoprotein cholesterol Pharmacology Polymorphism Single Nucleotide chemistry.chemical_compound Pharmacokinetics Asian People Double-Blind Method Internal medicine Genotype Medicine ATP Binding Cassette Transporter Subfamily G Member 2 Humans Pharmacology (medical) Rosuvastatin Rosuvastatin Calcium Lipoprotein cholesterol Aged Sulfonamides biology business.industry Cholesterol nutritional and metabolic diseases Cholesterol LDL Middle Aged Neoplasm Proteins Fluorobenzenes Endocrinology Pyrimidines chemistry biology.protein lipids (amino acids peptides and proteins) ATP-Binding Cassette Transporters Female business medicine.drug Follow-Up Studies |
| Zdroj: | Clinical pharmacology and therapeutics. 87(5) |
| ISSN: | 1532-6535 |
| Popis: | The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. We examined whether this polymorphism influences the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy of the drug. In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text